TCR-T cells
Phase 1Cell therapy
TCR-T cells is one of 126 biologic programs targeting Lung Cancer. It is currently in Phase 1.
4
Indications
8
Total Trials
6
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Rydapt
NovartisPhase 3
Nexavar
BayerPhase 3
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Retin-a
VValeant Pharmaceuticals
Phase 3
Bicnu
MMelissa K Accordino
Phase 3
Standard Chemotherapy
RochePhase 3
Oblimersen Sodium
NNational Cancer Institute (NCI)
Phase 3
APG-2575
Ascentage Pharma Group Inc.Phase 3
Daunorubicin or Idarubicin
NovartisPhase 3
Azacitadine
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Patients With Advanced Solid Tumors1 trial
Hepatocellular Carcinoma1 trial
Esophageal Adenocarcinoma1 trial
2 more indications
Lung Cancer1 trial
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT03778814·30 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing DCTY Biotech Co.,Ltd.